BioPharmSignal logoBioPharmSignal

Biotech News

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Sagimet Biosciences (SGMT)Sagimet BiosciencesConference / presentation

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46 th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here ).

Related news

SGMTSagimet Biosciences2026-05-13 11:00 EST

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

SGMTSagimet Biosciences2026-04-06 11:00 EST

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-05-27 12:00 EST

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

EMBCEmbecta2026-05-08 13:00 EST

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

View all latest news

Sagimet Biosciences

Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing...

Recent company news

SGMTSagimet Biosciences2026-08-04 11:00 EST

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

SGMTSagimet Biosciences2026-06-29 11:00 EST

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

SGMTSagimet Biosciences2026-06-23 00:49 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-05-27 11:00 EST

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

SGMTSagimet Biosciences2026-05-13 11:00 EST

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Stock data

Close
8.74 USD
Market cap
419.29M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States